Join
Live feed
·
PRReleasevia Quantisnow
Lexicon Pharmaceuticals Inc. logo

Lexicon Announces Topline Results From Phase 2 Proof-of-Concept Study of LX9211 in Postherpetic Neuralgia

ByQuantisnow·Wall Street's wire, on your screen.
LXRX· Lexicon Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track LXRX (Lexicon Pharmaceuticals Inc.) and more on Quantisnow.